Eledon Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 13, 2026, covering the quarterly period ended June 30, 2026, and disclosing going concern doubt and continued operating losses.

Key Highlights

  • Going concern warning: The filing states that the company's financial condition "raises substantial doubt as to our ability to continue as a going concern if we are unable to raise additional financing to fund our operations."
  • Shares outstanding: As of August 10, 2026, there were 81,261,152 shares of common stock outstanding.
  • Continued losses expected: The company disclosed it "has incurred significant operating losses since our inception and expects that we will continue to incur losses over the next several years and may never achieve or maintain profitability."
  • Additional funding required: According to the filing, the company will require additional capital to complete development of its lead drug candidate, and failure to raise such capital could force curtailment or cessation of operations.
  • Smaller reporting company: The registrant is classified as a non-accelerated filer and smaller reporting company, and is not an emerging growth company.

Eledon Pharmaceuticals Discloses Going Concern Risk and Funding Needs in June 2026 Quarterly Report

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a Delaware-incorporated clinical-stage pharmaceutical company headquartered in Irvine, California, submitted its Form 10-Q for the quarter ended June 30, 2026. The filing identifies several risks the company considers material to its business, centered on its ability to sustain operations without additional external financing.

According to the filing, the company has accumulated operating losses since inception and expects those losses to continue for "the next several years," with no assurance of ever achieving profitability. The registrant disclosed that if it cannot continue as a going concern, it "may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements." The filing also noted that future issuances of common stock, including shares potentially issuable under outstanding warrants or other convertible securities, could dilute existing stockholders and pressure the stock price.

The company's product candidates are described in the filing as being "in the early stages of clinical development." The filing cautions that non-clinical and early clinical trial results may not predict outcomes in later-stage trials, and that delays or difficulties in patient enrollment could postpone regulatory approvals and increase development expenses. The forward-looking statements contained in the report are the company's own and are subject to its cautionary language regarding risks and uncertainties as described in Part II, Item 1A of the filing.

What Was Disclosed

Eledon Pharmaceuticals filed a 10-Q for the quarter ended June 30, 2026, reporting 81,261,152 shares outstanding as of August 10, 2026, and disclosing going concern doubt, continued operating losses, and a need for additional financing to fund drug development activities.